Orveko also said this: "There is a patent application that would protect A2-73 as a monotherapy for the treatment of Alzheimer's, but it has been dormant for years. Maybe there is life in it yet - who knows? "
I am not worried about our intellectual property. We are making the filings for AD and there are no foreseeable competing claims or flaws. The uncertainty is in the efficacy.